Mateo A. Boulos

Binding to Albumin and Off-Target Toxicity Confound the Use of LRRC8/VRAC Channel Blockers in Cell Physiology Assays

It is demonstrated that most commercially available VRAC blockers limit proliferation and viability predominantly through VRAC-independent mechanisms, underscore the need for rigorous molecular controls in pharmacological studies and provide basis for developing more selective and less toxic VRAC-targeting agents.